Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

100.40 -1.44 (-1.41%)
Official Closing Price Updated: 7:00 PM EST, Dec 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S ADR

< Previous 1 2 3 4 5 6 7 8 9
...
30 31 Next >
Food and Beverage Stocks Look Appetizing After Ozempic Selloff
Investors should brush off Ozempic selloff fears and dive into tasty food and beverage stocks that have been oversold in 2023. 
Via InvestorPlace
Snack Maker Mondelez Int'l Is Down but Not Out
If Mondelez beats consensus for Q3 and can offer reassurance about the potential impact of Ozempic, investors’ appetite for chewed up snack makers may improve. 
Via MarketBeat
Why Is Alzheimer's Player Prothena Stock Trading Higher Today?
Prothena Corporation plc (NASDAQ: PRTA) is reportedly talking to advisors, potentially preparing for a sale. 
Via Benzinga
Barron's Weekend Stock Picks: Truist Financial, Groupon And Nvidia's Rising Stock
Benzinga reviews this weekend's top stories covered by Barron's. Here are the articles investors need to read. 
Via Benzinga
Why Novo Nordisk Stock Raced Higher Today
Wegovy and Ozempic should continue to be hot items at the pharmacy. 
Via The Motley Fool
This Is What Whales Are Betting On Novo Nordisk
Via Benzinga
Why Shares of Ardelyx Were Down Wednesday
The company's hopes for approval of a drug to treat chronic kidney disease took a hit. 
Via The Motley Fool
1 Big Risk Facing Ozempic, Wegovy, and Other GLP-1 Weight-Loss Drugs
Can concerns about side effects derail the growth of these incredibly popular drugs? 
Via The Motley Fool
Johnson & Johnson Stock: Is Now the Time to Sell?
Conservative investors buy Johnson & Johnson for the dividend, but that payout is less safe after its Kenvue spinoff 
Via InvestorPlace
Are Ozempic and Similar Treatments Impacting Food and Beverage Stocks? Here's What Pepsi's CFO Said About It
PepsiCo's Q3 earnings may have shed some light on the long-standing speculation about Ozempic's impact on consumer staples. 
Via The Motley Fool
Novo Nordisk Ups Outlook Amid Surging Demand For Weight Loss Drug Wegovy, Ozempic
Following a surge in demand for its weight-loss drug Wegovy and diabetes medication Ozempic, Novo Nordisk has revised its full-year outlook. 
Via Benzinga
Stock Market Rallies, Hits Resistance; Novo Nordisk, JPMorgan, Exxon In Focus: Weekly Review
The major indexes stalled at key levels amid weak breadth. 
Via Investor's Business Daily
Why Eli Lilly Stock Is Jumping Today
Good news for Novo Nordisk's Ozempic could be good news for Lilly's Mounjaro. 
Via The Motley Fool
Ozempic Weight Loss Drug Maker Is Making Money Hand Over Fist - And Just Raised Its Profit Forecast
Novo Nordisk A/S (NYSE: NVO) raised its FY23 guidance as sales of its block 
Via Benzinga
Momo Buys On Iran Hinting At Second Front And Israel Issuing An Impossible Evacuation Order
To gain an edge, this is what you need to know today. 
Via Benzinga
Why WW International Stock Was Bulking Up This Week
Its leading proponent effectively endorsed the company's recent pivot. 
Via The Motley Fool
Novo Nordisk's Kidney Outcomes Trial Has Broad Industry Implications
Novo Nordisk A/S (NYSE: NVO) shares got a boost this week after the drugmaker halted trials testing potential treatment for kidney failure on  
Via Benzinga
ChatGPT Parent OpenAI Aims At Budget-Friendly AI Innovations, Novo Nordisk's Popular Diabetes Drug Ozempic Faces Counterfeit Threat in Germany: Today's Top Stories
Bloomberg Apple and Suppliers Face Unanticipated Sales Slump Despite New Launches 
Via Benzinga
Topics Artificial Intelligence Supply Chain
Exposures Artificial Intelligence Supply Chain
Will Higher Ozempic Use Mean Slimmed-Down Food Sales?
Novo Nordisk's Ozempic, a weight loss drug, is making waves in the food industry, raising concerns about its effect on sales of calorie-laden products. 
Via MarketBeat
Novo Nordisk's Popular Diabetes Drug Ozempic Faces Counterfeit Threat in Germany
Germany's federal drug regulator, BfArM, has warned pharmacies and drug distributors in response to discovering counterfeit batches of Novo Nordisk's (NYSE: NVO) diabetes  
Via Benzinga
7 Affordable Stocks to Invest in as America’s Population Ages
Stocks for an aging population include some surprisingly youthful products and firms not commonly associated with seniors. 
Via InvestorPlace
Eli Lilly To Fly Higher? Fund Manager Gary Black Envisions Blockbuster Potential For Diabetes Drug Mounjaro
Lilly stock has been on a tear this year, thanks to the huge potential its GLP-1 agonist Mounjaro promises. 
Via Benzinga
Tempest Therapeutics, Microsoft, Birkenstock, Novo Nordisk, Tesla: Why These 5 Stocks Are On Investors' Radars Today
Major U.S. stock indices ended in the green on Wednesday, with the Nasdaq Composite marking notable gains of nearly 100 points. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Investors Punished Baxter International Stock Today
The latest data from the lab could spell trouble for the company. 
Via The Motley Fool
The Weight Loss Drug Gold Mine
U.S. healthcare providers wrote more than 9 million prescriptions for GLP-1 drugs in the final quarter of 2022, as demand soared for the blockbuster treatments. And one key company is reaping the... 
Via Talk Markets
Why Dialysis Stocks Plunged Today
Novo Nordisk indicated one of its diabetes drugs could also be used to treat kidney disease. Here's what investors need to know. 
Via The Motley Fool
Ozempic Alert: New Trial Causes DaVita (DVA) Stock to Plunge 20%
Ozempic may be able to treat kidney disease. This news has sent competitor DaVita into a tailspin as DVA stock plunges. 
Via InvestorPlace
What's Going On With Eli Lilly Stock Wednesday?
Eli Lilly And Co (NYSE: LLY) shares are trading higher Wednesday. 
Via Benzinga
What's Going On With Kidney Dialysis Provider Stocks Today?
DaVita Inc (NYSE: DVA), Fresenius Medical Care AG (NYSE: FMS), and Baxter International Inc (NYSE: BAX) shares fel 
Via Benzinga
Novo Nordisk Pops After Hinting Weight-Loss Drug Also Treats Kidney Disease
Semaglutide is the active ingredient behind three of Novo Nordisk's biggest products. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
30 31 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.